Good
Mostly Aligned
Patient Risk:
Low
Summary
Most oncology-relevant efficacy/indication and mechanism statements align with the provided label excerpts. Several safety and duration-related claims are only partially supported or are missing key label limitations (notably optimal duration and osteonecrosis wording). Patent/generic affordability/cost-effectiveness claims are unsupported by the prescribing information excerpts.
Category Scores
Accurate Statements
Fosamax is the brand name for the drug alendronate.
Label identifies FOSAMAX and active ingredient as alendronate/alendronate sodium.
Fosamax is prescribed to treat osteoporosis in postmenopausal women.
Section 1.1 indicates FOSAMAX for treatment of osteoporosis in postmenopausal women.
Fosamax is used to treat Paget's disease of bone.
Section 1.5 indicates FOSAMAX for treatment of Paget's disease of bone in men and women.
Alendronate, the active ingredient in Fosamax, belongs to the class of drugs known as bisphosphonates.
Label repeatedly refers to FOSAMAX as an oral bisphosphonate and describes bisphosphonate class effects.
Bisphosphonates work by slowing down bone loss.
Clinical Pharmacology describes reduction of bone resorption and progressive gains in bone mass (Section 12.1/12.2).
By reducing bone resorption, bisphosphonates help to maintain bone density.
Section 12.1/12.2 states alendronate reduces bone resorption leading to progressive gains in bone mass; Clinical Studies describe prevention of bone loss (Section 14.2).
By reducing bone resorption, bisphosphonates help to reduce the risk of fractures.
Section 1.1 states FOSAMAX reduces incidence of fractures including hip and spine; Section 14.1 describes fracture incidence reductions.
Fosamax can cause osteonecrosis of the jaw.
Section 6.2 includes localized osteonecrosis of the jaw in post-marketing experience.
Fosamax can cause atypical femur fractures.
Section 6.2 includes low-energy femoral shaft and subtrochanteric fractures and atypical fractures of other bones.
Fosamax can cause esophageal irritation.
Section 5.1 describes local irritation of the upper gastrointestinal mucosa and esophageal adverse experiences.
Fosamax can cause esophageal ulcers.
Section 6.2 lists esophageal ulcers.
Treatment duration for Fosamax depends on the individual's response and risk factors for fracture.
Section 1.6 requires periodic re-evaluation of need for continued therapy; low-risk patients may consider discontinuation after 3 to 5 years.
The original patent for alendronate sodium (Fosamax) has expired.
Not supported by provided label excerpts (this statement is listed separately as unsupported).
Unsupported Statements
Osteonecrosis of the jaw is a condition where the jawbone does not heal after injury or surgery.
Provided label excerpt does not define ONJ with this description.
Osteonecrosis of the jaw can lead to pain, swelling, and infection.
Provided label excerpt does not specify these symptom outcomes for ONJ.
Bisphosphonates inhibit osteoclasts, the cells responsible for breaking down bone tissue.
Label states alendronate inhibits osteoclast activity; it does not explicitly define osteoclasts as 'cells responsible for breaking down bone tissue' in the provided excerpt.
Fosamax treatment is typically continued as long as the drug is considered beneficial and the risks are outweighed by the benefits.
Section 1.6 in the provided excerpt focuses on re-evaluating need for continued therapy and discontinuation considerations; it does not phrase it as 'risks are outweighed by the benefits.'
The expiration of the alendronate sodium (Fosamax) patent allows for the availability of generic versions.
Patent/generic availability is not addressed in the provided label excerpts.
Following the expiration of its patents, multiple pharmaceutical companies have introduced generic versions of alendronate.
Not addressed in provided label excerpts.
Generic versions of alendronate offer more affordable treatment options.
Affordability/cost claims are not addressed in provided label excerpts.
Fosamax (alendronate) is often a first-line treatment due to its efficacy and cost-effectiveness.
Label excerpts provided do not include 'first-line' or cost-effectiveness/efficacy framing.
The choice of osteoporosis treatment depends on individual patient factors including bone mineral density, fracture history, and tolerance to medication.
Provided label excerpt does not list these decision factors in this way.
Switching from Fosamax to another osteoporosis medication may be considered if side effects are not tolerated.
The provided label excerpt does not provide guidance on switching to another osteoporosis medication based on side effects.
Switching from Fosamax to another osteoporosis medication may be considered if the drug is not sufficiently effective.
The provided label excerpt does not provide guidance on switching based on insufficient effectiveness.
Contradictions
Important Omissions
For osteoporosis treatment duration: label emphasizes that optimal duration has not been determined, safety/effectiveness based on 4 years clinical data, periodic re-evaluation, and that low-risk patients should be considered for discontinuation after 3 to 5 years with periodic re-evaluation after discontinuation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The safety-related claims (ONJ, atypical femur fractures, esophageal irritation/ulcers) are broadly supported as adverse experiences, but some symptom definitions and duration phrasing are unsupported/partially supported. Non-label patent/generic cost/switching guidance could mislead if treated as label-based.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the provided prescribing information excerpts (especially ONJ symptom definition and patent/generic affordability/cost-effectiveness and treatment-switching considerations).
Suggested Improvement
Restrict statements to label-supported content: use Section 1.6 language for duration and re-evaluation; avoid non-label patent/generic/cost-effectiveness and non-label switching guidance; omit symptom descriptions not explicitly stated in the provided label.